Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete |